Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Maintenance of autoantibody production in pristane-induced murine lupus

Fig. 2

B cell subsets in spleen from pristane-treated vs. PBS treated mice. Spleen cells from pristane-treated (1 year) and age-matched PBS treated mice were stained with anti-CD19, CD138, IgM, and IgD antibodies and analyzed by flow cytometry. a Gating strategy for CD19+CD138+ plasmablasts (PB) and CD19+/−CD138++ plasma cells (PC) (top) and CD19+CD138IgM+IgD+ naïve B cells (NB), and CD19+CD138IgMIgD switched-memory B cells (sMB) (bottom) are shown on the left. Percentages of PB and PC in spleen from pristane-treated and untreated mice are on the top right and percentages of NB and sMB in CD19+CD138 cells are on the bottom right. b The gating strategy for CD19+CD138IgMIgD+ and CD19+CD138IgD+ cells is the same as a. The percentage of CD19+CD138IgMIgD+ and CD19+CD138IgD+ cells in CD19+CD138 cells in spleens from pristane-treated and untreated mice are shown: *p <0.05; **p <0.01, Mann–Whitney test

Back to article page
\